LVRT Levrett

TIDMNFX

Nuformix PLC

15 February 2023

REACH

15 February 2023

Nuformix plc

("Nuformix" or the "Company" or the "Group")

NXP002 Update

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the following update regarding the Company's NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled treatment for Idiopathic Pulmonary Fibrosis ("IPF").

As previously announced, the Company has initiated studies in 3D human IPF lung tissue using a disease and species relevant model, and is working with its partner, Fibrofind, focusing on NXP002 in combination with current standards of care . Suitable human disease tissue, which is highly limited in supply, has now been acquired allowing the practical elements of the study to commence, with results and further updates to be announced in due course.

NXP002 combinations have already shown promise in human diseased IPF tissue, showing a pleasing synergistic efficacy effect with low doses of standards-of-care, resulting in the Group filing a new combination patent application in 2022.

Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: " We've had to wait a little longer than expected to acquire suitable tissue, but I'm delighted that the main element of this key study, further evaluating NXP002 combination therapies is now underway and I look forward to sharing the results when they are available."

Enquiries:

 
 Nuformix plc 
 Dr Dan Gooding, Executive Director         Via IFC Advisory 
 Stanford Capital Partners Limited 
 Tom Price / Patrick Claridge (Corporate 
  Finance)                                  +44 (0) 20 3650 3650 
 John Howes (Corporate Broking)             +44 (0) 20 3650 3652 
 IFC Advisory Limited 
 Tim Metcalfe                               +44 (0) 20 3934 6630 
  Zach Cohen                                 nuformix@investor-focus.co.uk 
 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

About Fibrosis

Fibrotic disease is typically associated with high patient mortality, increasing prevalence and a lack of safe and effective treatments. Whilst fibrosis treatments are in their infancy the emerging lung fibrosis market demonstrates their blockbuster potential. Idiopathic Pulmonary Fibrosis is classified as a rare disease and presents a global commercial market that is forecast to grow to US$5bn by 2025. Sales of standard-of-care therapies OFEV and Esbriet achieved US$2.58bn and US$1.04bn respectively in 2021.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABZLFFXLLZBBK

(END) Dow Jones Newswires

February 15, 2023 02:00 ET (07:00 GMT)

Levrett (LSE:LVRT)
Historical Stock Chart
From Apr 2024 to May 2024

Levrett (LSE:LVRT)
Historical Stock Chart
From May 2023 to May 2024